This open-label study (n=8) co-administered psilocybin (25mg) with the amnestic benzodiazepine midazolam to assess the role of memory in the therapeutic effects of psilocybin. It finds that midazolam partially impaired memory while allowing a conscious psychedelic experience, with memory impairment inversely associated with salience, insight, and well-being induced by psilocybin, suggesting a role for memory in its therapeutic effects.
- Published
- Journal
- Translational Psychiatry
- Authors
- Nicholas, C. R., Banks, M. I., Lennertz, R. L., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R. F., Hutson, P. R., Sauder, C. J., Dunne, J. D., Roseman, L., Raison, C. L., Banks, M. I.